

CD45+
macrophages
% of live cells in tumor
mean +/- SEM
500
400
300
200
100
0
week 2
week 4
100
75
50
25
0
week 4
Vehicle
control ASO
muSTAT3 ASO

Figure 1



Tumor Volume (mm3), mean +/- SEM
1250
1000
750
500
250
0
5
10
15
20
25
30
35
Days after implant
Control Ab 5 mg/kg, 2X/wk (d9)
Vehicle
muSTAT3 ASO 50 mg/kg, QDx5/wk (d9)
PD-L1 Ab 5 mg/kg, 2X/wk (d9)
PD-L1 Ab (d9) + muSTAT3 ASO (d9)
muSTAT3 ASO 50 mg/kg, QDx5/wk (d2)
PD-L1 Ab (d9) + muSTAT3 ASO (d2)

Figure 2a




Figure 2b




Figure 2c



PD-L1, CT-26 tumors
CTLA-4, CT-26 tumors
OX40 FP, CT-26 tumors
TUMOR VOLUME, mm3 +/- SEM
DAYS AFTER RANDOMISATION
Vehicle
muSTAT3 ASO 50 mg/kg
PD-L1 Ab 5 mg/kg
CTLA-4 Ab 5 mg/kg
OX40 FP 7.5 mg/kg
combination

Figure 3a



PD-L1, 4T1 tumors
CTLA-4, 4T1 tumors
OX40 FP, 4T1 tumors
TUMOR VOLUME, mm³ +/- SEM
DAYS AFTER RANDOMISATION
Vehicle
muSTAT3 ASO 50 mg/kg
PD-L1 5 mg/kg
CTLA-4 Ab 5 mg/kg
OX40 FP Ab 7.5 mg/kg
combination
0
400
800
1200
1600
2000
0
5
10
15
20

Figure 3b



PD-L1, A20 tumors
CTLA-4, A20 tumors
OX40 FP, A20 tumors
TUMOR VOLUME, mm3 +/- SEM
DAYS AFTER RANDOMISATION
0
400
800
1200
1600
0
5
10
15
20
Vehicle
muSTAT3 ASO 50 mg/kg
PD-L1 Ab 5 mg/kg
CTLA-4 Ab 5 mg/kg
OX40 FP Ab 7.5 mg/kg
combination

Figure 3c




Figure 4




Figure 5




Figure 6




Figure 7